Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

stocks2

Valeant bondholders issue notice to default

April 13, 2016 Research and Development, Sales and Marketing Valeant, bondholders, default, fears, possibility

Valeant (NYSE: VRX) has issued a statement detailing plans from some of its bondholders to call a default because of …
News
chemo-web

EUSA Pharma acquires global rights to oncology support drug

April 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Eusa Pharma, acroral, acroral tab, global rights, oncology

EUSA Pharma has announced the acquisition of global rights to oncology support care product, Arcoral Tab, from Arcoral Pharma.
News
regeneron

Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology

April 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics

Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
News
dollars_medicines

KaloBios announces new affordable pricing model, refuses to engage in “price gouging”

April 12, 2016 Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible

Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
News
roche

Roche’s Venclexta gets accelerated approval from US FDA for chronic lymphocytic leukemia

April 12, 2016 Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Roche, US FDA, Venclexta, chronic lymphocytic leukemia

Swiss drug firm Roche (SIX: ROG) on Tuesday said the US Food and Drug Administration (FDA) has granted accelerated approval …
News
shutterstock_4030507

Insys Therapeutics sees revenue from Subsys at $61-$62 million; shares plunge 21%

April 11, 2016 Business Services, Manufacturing and Production, Sales and Marketing Insys Therapeutics, Stock Price, Subsys, opioids, pain drug

Insys Therapeutics Inc (Nasdaq: INSY) stock plunged nearly 21% Monday after the company said sales for its pain drug will …
News
stocks1

Weekly Movers: Array BioPharma, Amicus Therapeutics, Genocea Biosciences, Tesaro Inc, Incyte, Clovis Oncology

April 11, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Index, Movers, markets, stocks

Shares in Botox-maker Allergan (NYSE: AGN) plunged over 17% in intra-day trading as the $160 billion merger seal with US …
Feature
money_pills_2

Depomed criticised by investors and urged to explore potential sale

April 11, 2016 Sales and Marketing Depomed, board, horizon, sale, starboard, starboard value

Only a few short months after fighting off a $1 billion bid from Horizon Pharma, investors at Depomed have called …
News
roche__tree

Roche’s cancer immunotherapy for lung cancer gets US FDA priority review

April 11, 2016 Business Services, Research and Development, Sales and Marketing Roche, US FDA, atezolizumab, lung cancer

Swiss drug firm Roche (SIX: ROG) on Monday said the US Food and Drug Administration (FDA) has accepted its Biologics …
News
chemo-web

Midatech launch treatment to reduce chemo-induced vomiting in the US

April 11, 2016 Research and Development, Sales and Marketing chemotherapy, midatech, nausea, oncology, radiation, vomiting

Midatech Pharma (NASDAQ: MTP) has the full commercial launch of Zuplenz (ondansetron) in the US. The drug is an oral …
News
640px-eye_iris

Sun Pharma receives FDA approval for ocular pain treatment

April 11, 2016 Research and Development, Sales and Marketing FDA, Sun Pharma, bromsite, ocular treatment

Sun Pharma (BSE: 524715) has announced that their ocular pain prevention treatment, BromSite (bromfenac ophthalmic solution), has been approved by …
News
celgene-logo

Celgene says disappointed with NICE decision to not back blood cancer drug

April 8, 2016 Business Services, Medical Communications, Sales and Marketing

US drugmaker Celgene Corp (Nasdaq: CELG) on Friday said it is disappointed with UK regulators’ decision to not recommend Vidaza …
News
fda2outsideweb

US panel supports accelerated approval for Intercept’s trial drug for rare liver condition

April 8, 2016 Medical Communications, Research and Development, Sales and Marketing Intercept Pharmaceuticals, PDUFA, US FDA, liver disorder, rare disease

Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …
News
apps_mobile

FTC launches tool to help mobile health app developers determine applicable regulations

April 8, 2016 Medical Communications, Sales and Marketing FDA, FTC, apps, health, health apps, regulation

The US Federal Trade Commission has created a new web-based tool for developers of health-related mobile apps to help them …
News

Vectura to get $10 million milestone as Hikma files ANDA for generic copy of GSK’s asthma drug

April 8, 2016 Medical Communications, Research and Development, Sales and Marketing

Vectura Group (LSE: VEC) on Friday said it is set to receive $10 million in milestone payments from partner Hikma …
News
The Gateway to Local Adoption Series

Latest content

IsomAb appoints Philip Brainin as CEO

March 19, 2026

Naobios partners with SGS to manufacture RSV challenge agent

March 19, 2026

Qlaris Bio appoints Fred Guerard as President and CEO

March 18, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

March 18, 2026

AEON Biopharma appoints John Bencich as CFO

March 17, 2026